Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 50,434 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer, Clear all
Recruiting Phase 2 Interventional

BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

NCT07002216
View directory record Official record
Conditions
Hodgkin Lymphoma, Advanced Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, Dexamethasone
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Nov 13, 2026, 5:56 AM EST
Completed Phase 1 Interventional

Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer

NCT00476216
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Venous Thromboembolism
Interventions
Combination of Arixtra with chemotherapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Nov 13, 2026, 5:56 AM EST
No Longer Available No phase listed Expanded access

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

NCT00302016
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
AMN107
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
59
States / cities
Mobile, Alabama • Tucson, Arizona • Duarte, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2011 · Synced Nov 13, 2026, 5:56 AM EST
Withdrawn Phase 1Phase 2 Interventional

Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy

NCT00256841
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Chemotherapy, Radiation Therapy
Drug · Procedure
Lead sponsor
Clinical Oncology Research Associates
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Nov 13, 2026, 5:56 AM EST
Completed Not applicable Interventional Results available

Improving Uptake of Genetic Cancer Risk Assessment in African American Women- Video

NCT04476654
View directory record Official record
Conditions
Breast Cancer
Interventions
YouTube Video Arm
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Nov 13, 2026, 5:56 AM EST
Completed Phase 2 Interventional Results available

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

NCT00666666
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage IV Prostate Cancer
Interventions
AT-101, Bicalutamide, LHRH agent
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Nov 13, 2026, 5:56 AM EST
Recruiting No phase listed Observational

Establishment of a Lifetime of Cohort of Adults Surviving Childhood Cancer

NCT00760656
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2035
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 13, 2026, 5:56 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study of Ivonescimab in People With Non-Small Cell Lung Cancer

NCT07594522
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Photon or Proton standard stereotactic body radiotherapy (SBRT), Ivonescimab
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Nov 13, 2026, 5:56 AM EST
Active, not recruiting Phase 2 Interventional

89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

NCT04006522
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
89Zr-DFO-Atezolizumab, Positron Emission Tomography/Computed Tomography
Drug · Procedure
Lead sponsor
James Brugarolas
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 13, 2026, 5:56 AM EST
Recruiting Phase 3 Interventional

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
67
States / cities
Gilbert, Arizona • Tucson, Arizona • Clovis, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 5:56 AM EST
Terminated Phase 2 Interventional Results available

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

NCT03488251
View directory record Official record
Conditions
Non-hodgkin Lymphoma,B Cell, Refractory Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma
Interventions
MT-3724, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
9
States / cities
Orange, California • Santa Monica, California • Whittier, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Nov 13, 2026, 5:56 AM EST
Completed Phase 2 Interventional

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

NCT00055653
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, cyclosporine, fludarabine phosphate, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
25
States / cities
Duarte, California • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Nov 13, 2026, 5:56 AM EST
Recruiting Not applicable Interventional

Microvideos for Improving HPV Vaccination Among Childhood Cancer Survivors

NCT07648953
View directory record Official record
Conditions
HPV Vaccination
Interventions
Microvideos: HPV Vaccination Education
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 26 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 13, 2026, 5:56 AM EST
Terminated No phase listed Observational

Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban

NCT04895553
View directory record Official record
Conditions
Glioma, Malignant
Interventions
Observation of ICH and VTE
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Sacramento, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Nov 13, 2026, 5:56 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule

NCT07219537
View directory record Official record
Conditions
Lynch Syndrome, Crohn Disease, Inflammatory Bowel Diseases, Healthy
Interventions
Feasibility of using an OCT-based Retrograde Tethered Capsule Endomicroscope device to image the lower GI tract
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Nov 13, 2026, 5:56 AM EST
Completed Phase 2 Interventional Results available

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

NCT04369937
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
IMRT (Intensity Modulated Radiotherapy), Pembrolizumab, Cisplatin, ISA101b
Radiation · Drug · Biological
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 13, 2026, 5:56 AM EST
Completed No phase listed Observational

Predicting Disease Progression and/or Recurrence in Cancer

NCT04776837
View directory record Official record
Conditions
Patient Reported Outcome Measures, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer, Esophageal Cancer, Metastatic Cancer, Disease Progression, Survival Analysis
Interventions
Observational Cohort
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 13, 2026, 5:56 AM EST
Terminated Phase 2 Interventional Results available

Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer

NCT00383331
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
Pemetrexed, Gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Nov 13, 2026, 5:56 AM EST
Terminated Phase 2 Interventional Results available

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

NCT00722072
View directory record Official record
Conditions
Breast Cancer
Interventions
fulvestrant, sorafenib tosylate
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Nov 13, 2026, 5:56 AM EST
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

NCT00002995
View directory record Official record
Conditions
Sarcoma
Interventions
dactinomycin, filgrastim, sargramostim, cyclophosphamide, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2011
U.S. locations
205
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Nov 13, 2026, 5:56 AM EST
Recruiting Phase 2 Interventional

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

NCT06458439
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Epcoritamab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Nov 13, 2026, 5:56 AM EST
Completed Phase 3 Interventional

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)

NCT01147939
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Elacytarabine, Investigator's Choice
Drug
Lead sponsor
Clavis Pharma
Industry
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2013 · Synced Nov 13, 2026, 5:56 AM EST
Terminated Phase 3 Interventional

VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM

NCT03149575
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma, Glioma, GBM, Brain Cancer
Interventions
VAL-083, Dianhydrogalactitol, Physician's Choice of Salvage Therapy - temozolomide, Physician's Choice of Salvage Therapy - lomustine, Physician's Choice of Salvage Therapy - carboplatin
Drug
Lead sponsor
DelMar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Nov 13, 2026, 5:56 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

NCT02163057
View directory record Official record
Conditions
Head and Neck Squamous Cell Cancer
Interventions
INO-3112, CELLECTRA™-5P
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Nov 13, 2026, 5:56 AM EST